Acute Myeloid Leukemia — Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Citation(s)
A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies